1/12
08:55 am
sndx
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/12
07:00 am
sndx
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
1/11
01:03 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at
Wall
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by analysts at
Wall
1/7
07:00 am
sndx
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Medium
Report
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
1/5
07:00 am
sndx
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
1/3
01:08 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at
Wall St
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) was upgraded by analysts at
Wall St
12/17
08:17 am
sndx
Syndax Pharma: Continuing Execution In AML [Seeking Alpha]
Low
Report
Syndax Pharma: Continuing Execution In AML [Seeking Alpha]
12/12
07:00 am
sndx
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Low
Report
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
12/9
08:07 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.
12/8
06:50 am
sndx
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Medium
Report
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
12/3
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12/1
07:13 am
sndx
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
Medium
Report
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference [Yahoo! Finance]
12/1
07:00 am
sndx
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Medium
Report
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
11/29
10:12 pm
sndx
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]
Medium
Report
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth [Seeking Alpha]
11/28
12:09 pm
sndx
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]
Low
Report
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating [Yahoo! Finance]
11/26
02:19 pm
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:44 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $22.00 to $35.00. They now have an "overweight" rating on the stock.
Medium
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $22.00 to $35.00. They now have an "overweight" rating on the stock.
11/17
07:26 pm
sndx
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge [Yahoo! Finance]
Low
Report
Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge [Yahoo! Finance]
11/16
10:26 pm
sndx
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating [Yahoo! Finance]
Low
Report
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating [Yahoo! Finance]
11/12
12:22 pm
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "overweight" rating on the stock.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "overweight" rating on the stock.
11/10
02:04 pm
sndx
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Syndax Pharmaceuticals, Inc. (SNDX) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/6
05:50 am
sndx
Analyst Estimates: Here's What Brokers Think Of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter Report [Yahoo! Finance]
Low
Report
Analyst Estimates: Here's What Brokers Think Of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Third-Quarter Report [Yahoo! Finance]
11/5
04:01 pm
sndx
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/4
11:05 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at UBS Group AG from $35.00 to $38.00. They now have a "buy" rating on the stock.
Low
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at UBS Group AG from $35.00 to $38.00. They now have a "buy" rating on the stock.
11/4
09:06 am
sndx
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $19.00 to $22.00. They now have an "overweight" rating on the stock.
High
Report
Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target raised by analysts at Barclays PLC from $19.00 to $22.00. They now have an "overweight" rating on the stock.